Refeyn launches software platform to automate mass photometry workflows
Refeyn's new software automates mass photometry workflows, delivering faster and more consistent results for bioanalytical applications.
List view / Grid view
Refeyn's new software automates mass photometry workflows, delivering faster and more consistent results for bioanalytical applications.
Novartis has teamed up with PTC Therapeutics to develop PTC518, a groundbreaking treatment that targets the cause of Huntington's disease, offering new hope for patients.
Regulatory changes are reshaping toxicology, with precision now at the forefront. We explore how accurate target analysis is transforming drug development, particularly for biotherapeutics.
The global small molecule drug discovery market is set for significant growth. Explore the key factors driving this expansion, from rising R&D investments to the increasing role of AI and CROs.
To fully unlock the potential of immunotherapy for cancer patients, we need better targets, not just better treatments. Hear from Michelle Teng, CEO of Etcembly, on how AI is decoding the immune repertoire and designing new therapies.
Alex Bonnyman is transforming protein manufacturing while championing women in STEM. Explore her journey of innovation, resilience, and inclusivity in biotechnology.
Scientists have decoded the 3D structure of a key enzyme linked to Alzheimer's disease. This breakthrough opens up new possibilities for targeted drug development and better treatment options.
Eurofins Healthcare Assurance is expanding into China to better serve key industries with local expertise. This move strengthens their commitment to quality assurance and regulatory services on a global scale.
By acquiring Evotec, Halozyme aims to enhance drug discovery and delivery, driving substantial growth in the pharmaceutical sector.
Insilico Medicine’s AI-designed drug ISM5939 has received FDA IND clearance for treating solid tumours. By targeting ENPP1, it enhances anti-tumour immunity and is set to begin Phase I trials soon.
Obecabtagene autoleucel (obe-cel) has demonstrated strong efficacy in treating relapsed B-cell leukemia, with high response rates and minimal side effects.
A new blood-brain barrier-crossing platform enables the delivery of therapeutic molecules to the brain, offering potential treatments for ALS and Alzheimer’s disease.
New collaboration focuses on transforming academic research into innovative therapies for urgent medical conditions, including cancer and heart disease.
Founder and CSO of Achilles Therapeutics Dr Sergio Quezada reveals how the landmark TRACERx study has gleaned key insights that could make the difference between success and failure in immunotherapy treatment.
Researchers in the US have developed a new CRISPR method for treating genetic conditions using nickases that they say is safer and more effective.